SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

[1]  S. Gery,et al.  Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.

[2]  Gary K. Chen,et al.  Copy number alterations in prostate tumors and disease aggressiveness , 2012, Genes, chromosomes & cancer.

[3]  I. Laczmanska,et al.  Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. , 2011, Acta biochimica Polonica.

[4]  Chris T. Harvey,et al.  HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to Hypoxia* , 2011, The Journal of Biological Chemistry.

[5]  D. Goldenberg,et al.  Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers. , 2011, Blood.

[6]  N. Munshi,et al.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.

[7]  C. Eberhart,et al.  Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Glioblastoma Growth , 2011, Journal of neuropathology and experimental neurology.

[8]  S. South,et al.  American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants , 2011, Genetics in Medicine.

[9]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[10]  J. Lowe,et al.  Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. , 2011, Neuro-oncology.

[11]  F. Zhan,et al.  Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2 , 2010, Cancer biology & therapy.

[12]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[13]  A. Gingras,et al.  Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1 , 2010, Nature.

[14]  L. Staudt,et al.  Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. , 2010, Blood.

[15]  N. Gutiérrez,et al.  The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells , 2010, Clinical Cancer Research.

[16]  L. Dillon,et al.  DNA Instability at Chromosomal Fragile Sites in Cancer , 2010, Current genomics.

[17]  G. Morgan,et al.  Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.

[18]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[19]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[20]  T. Misteli,et al.  Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma , 2009, Proceedings of the National Academy of Sciences.

[21]  V. Pantesco,et al.  Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells , 2009, British journal of haematology.

[22]  R. Kooy.  Fragile sites and human disease , 2009 .

[23]  G. Morgan,et al.  Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.

[24]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[25]  E. Wagner,et al.  Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia , 2008, Nature.

[26]  H. Klamová,et al.  CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. , 2008, Blood cells, molecules & diseases.

[27]  L. Staudt,et al.  Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. , 2007, Blood.

[28]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[29]  E. Vellenga,et al.  Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. , 2007, Blood.

[30]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[31]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[32]  D. Steinemann,et al.  Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. , 2007, Haematologica.

[33]  A. Hui,et al.  4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. , 2007, Blood.

[34]  Jens Timmer,et al.  Using High-density Snp Arrays Genome-wide Analysis of Dna Copy Number Changes and Loh in Cll , 2022 .

[35]  G. Morgan,et al.  Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. , 2006, Clinical lymphoma & myeloma.

[36]  L. Feuk,et al.  Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome , 2006, Cytogenetic and Genome Research.

[37]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[38]  R. Richards,et al.  Common chromosomal fragile sites and cancer: focus on FRA16D. , 2006, Cancer letters.

[39]  T. Glover.  Common fragile sites. , 2006, Cancer letters.

[40]  R. Bernards,et al.  The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.

[41]  L. Rémy,et al.  Matrilysine 1 et pathologie cancéreuse , 2005 .

[42]  U. Jäger,et al.  Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma , 2004, Leukemia.

[43]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[44]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[45]  Martins Marta,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia , 2003, Cancer.

[46]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[47]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[48]  J. Weitzman,et al.  JunD protects cells from p53-dependent senescence and apoptosis. , 2000, Molecular cell.

[49]  S. Knuutila,et al.  Online access to CGH data of DNA sequence copy number changes. , 2000, The American journal of pathology.

[50]  R. Bataille,et al.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Blood.

[51]  E. Schröck,et al.  Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.

[52]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[53]  K. Franssila,et al.  Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma , 1998, Genes, chromosomes & cancer.

[54]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.

[55]  L. Escoda,et al.  Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis , 2007, Leukemia.

[56]  L. Rémy,et al.  [Matrilysin-1 and cancer pathology]. , 2005, Medecine sciences : M/S.

[57]  A. Órfão,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. , 2003, Cancer.

[58]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.